Inmune Bio Signs Uniphar Commercial Pact, Pulls UK MAA Filing Forward to Feb 2027
INMB sits 55% above its 52-week low of $1.09 on light trading volume (0.2× avg).
Summary
Inmune Bio signed Uniphar to run named-patient access and distribution for Ebstrocel in Europe and MENA, and revised its UK plan to a full MAA filing in February 2027 that could bring potential approval forward by about six weeks.
Key Events · Product Development and Regulatory · INMB
-
Uniphar Commercialization Framework Signed
A Master Services Agreement with Uniphar Durbin Ireland Limited covers named-patient access in selected European countries and MENA, with potential expansion to broader distribution as approvals, pricing and reimbursement are secured. Services are implemented through country-specific statements of work.
-
UK MAA Filing Pulled Forward
The final pre-MAA package was submitted to the MHRA on October 20, 2026. Instead of a rolling submission starting late 2026, the company now plans a complete MAA in early February 2027, which it says could accelerate potential UK approval by roughly six weeks to mid-2027.
-
U.S. BLA Targeted for Q2 2027
Inmune Bio is preparing a Type B meeting request with the FDA and plans a BLA in Q2 2027, seeking traditional or accelerated approval. The FDA filing is now prioritized ahead of the EMA submission.
-
No Revenue or Approval Assured
Ebstrocel remains investigational and unapproved by the FDA, MHRA or EMA. The Uniphar relationship generates no stated revenue until statements of work are executed and local permissions granted; the company carried a going-concern warning in its August 2026 10-Q.
Analysis · INMB · Life Sciences
Two developments stand out. First, Inmune Bio has signed a Master Services Agreement with Uniphar to handle named-patient access, distribution and order-to-cash for Ebstrocel in selected European and MENA markets — a capital-light way to start generating revenue before formal approvals, without building country infrastructure itself. Second, the UK filing plan has changed: rather than a rolling submission starting late 2026, the company now intends to file a complete MAA in early February 2027, which it says could pull potential UK approval forward by about six weeks to mid-2027, with a U.S. BLA targeted for Q2 2027. No dollar figures, no revenue guidance and no approval are assured — the Uniphar work only proceeds through country-specific statements of work, and Ebstrocel remains investigational. Commercial value hinges on MHRA and FDA decisions in 2027, against a balance sheet that carried a going-concern warning as of the August 10-Q.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 29.1% of the 1524 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INMB was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.4M. The 52-week trading range was $1.09 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.